Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$41.15

(0.00%)

, GILD

Gilead

$70.72

(0.00%)

09:23
06/14/18
06/14
09:23
06/14/18
09:23

GSK two-drug HIV regimen meets primary endpoint in Phase III study

GlaxoSmithKline's (GSK) ViiV Healthcare announced "positive headline results" from its phase III Gemini study program. The studies are designed to evaluate the safety and efficacy of a two-drug regimen of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine, in treatment naive HIV-1 infected adults with baseline viral loads less than 500,000 copies per ml. The studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA less than 50 copies per millilitre at week 48. The safety results for the two-drug regimen of dolutegravir and lamivudine were consistent with the product labelling for the medicines, the company said. No patient who experienced virologic failure in either treatment arm developed treatment-emergent resistance. ViiV Healthcare will now plan for regulatory submissions for the two-drug regimen of dolutegravir and lamivudine later this year. "The GEMINI studies demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination. They affirm our two-drug regimen strategy, and reinforce our belief that many patients can control their disease with two drugs instead of three or more. Importantly, the studies show that this two-drug regimen could be an option for treatment naive patients and can support a broad range of patients living with HIV around the world," said John Pottage, Chief Scientific and Medical Officer of ViiV Healthcare. Shares of GlaxoSmithKline are up 88c to $42.02 in premarket trading. Shares of Gilead (GILD) are down 22c to $71.07.

GSK

GlaxoSmithKline

$41.15

(0.00%)

GILD

Gilead

$70.72

(0.00%)

  • 14

    Jun

  • 14

    Jun

  • 19

    Jun

  • 25

    Jun

  • 25

    Jul

GSK GlaxoSmithKline
$41.15

(0.00%)

04/04/18
04/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Buy from Hold at HSBC. 2. GlaxoSmithKline (GSK) upgraded to Outperform from Neutral at Exane BNP Paribas. 3. BHP Billiton (BHP) upgraded to Sector Perform from Underperform at RBC Capital and to Buy from Neutral at Citi. 4. Boston Beer (SAM) upgraded to Market Perform from Underperform at Cowen with analyst Vivien Azer citing strong Nielsen data in the non-beer category. 5. EnLink Midstream Partners (ENLK) upgraded to Overweight from Neutral at JPMorgan with analyst Jeremy Tonet saying he reduced his distribution growth expectations given the elevated cost of equity, but views the current 11.5% yield as sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
GILD Gilead
$70.72

(0.00%)

05/02/18
JEFF
05/02/18
NO CHANGE
Target $95
JEFF
Buy
Gilead turnaround thesis unchanged after Q1 results, says Jefferies
Jefferies analyst Michael Yee says that while Gilead Sciences last night didn't report the best quarter, the turnaround thesis remains unchanged. The results won't prove the thesis to bears, but Gilead's turnaround is underway and should play out over the next four quarters, Yee tells investors in a post-earnings research note. The stock, trading at an 11-12 times price-to-earnings ratio, is "cheap" and the worst is mostly behind the company, Yee adds. He keeps a Buy rating on Gilead with a $95 price target.
05/02/18
MAXM
05/02/18
NO CHANGE
Target $89
MAXM
Buy
Gilead price target lowered to $89 from $94 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Gilead to $89 after the company's Q1 results missed consensus, driven by lower than expected HIV/HBV revenues. The analyst has also reduced his FY18 EPS view to $6.14 from $6.74 and revenue to $20.5B from $21.4B, adding that while CAR-T treatment is promising, it is still a long way away. McCarthy keeps his Buy rating on Gilead, noting the company's "multiple" catalysts in 2018-2019 along with its $32B cash cushion that can expand the pipeline through M&A.
05/30/18
PIPR
05/30/18
INITIATION
Target $85
PIPR
Overweight
Gilead assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Gilead Sciences (GILD) with an Overweight rating and $85 price target. The analyst, after speaking with management, has a "high level of conviction" that pricing for the hepatitis C virus franchise has finally stabilized. It is inconceivable that AbbVie (ABBV) will continue to be irrational on pricing, Van Buren tells investors in a research note.
06/07/18
JEFF
06/07/18
NO CHANGE
Target $95
JEFF
Buy
Gilead turnaround happening this year, says Jefferies
After meeting with management, Jefferies analyst Michael Yee believes a turnaround at Gilead Sciences is happening this year. The analyst says Gilead remains his best large-cap idea for the turnaround and that the stock remains the most under-owned large cap. Yee expects the shares to rise on a potential positive Q2 result which would signal a turnaround and a view that the company is turning the corner in 2018. Further, the "big" Phase III NASH data call option in the first half of 2019 could "quickly move the stock" toward $95, Yee writes. He keeps a Buy rating on the shares with a $95 price target.

TODAY'S FREE FLY STORIES

RYTM

Rhythm Pharmaceuticals

$26.45

0.21 (0.80%)

22:08
06/20/18
06/20
22:08
06/20/18
22:08
Syndicate
Rhythm Pharmaceuticals 5.732M share Secondary priced at $26.42 »

Morgan Stanley,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 21

    Jun

AMCX

AMC Networks

$67.45

1.28 (1.93%)

22:06
06/20/18
06/20
22:06
06/20/18
22:06
Downgrade
AMC Networks rating change at Bernstein »

AMC Networks downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

APTX

Aptinyx

$0.00

(0.00%)

20:45
06/20/18
06/20
20:45
06/20/18
20:45
Syndicate
Aptinyx 6.4M share IPO priced at $16.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

AVRO

AvroBio

$0.00

(0.00%)

20:44
06/20/18
06/20
20:44
06/20/18
20:44
Syndicate
AvroBio 5.25M share IPO priced at $19.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

TV

Televisa

$18.25

0.51 (2.87%)

20:43
06/20/18
06/20
20:43
06/20/18
20:43
Downgrade
Televisa rating change at Scotiabank »

Televisa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

Cemex

$6.33

0.115 (1.85%)

20:42
06/20/18
06/20
20:42
06/20/18
20:42
Upgrade
Cemex rating change at Santander »

Cemex upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$164.49

0.74 (0.45%)

20:41
06/20/18
06/20
20:41
06/20/18
20:41
Downgrade
Parker-Hannifin rating change at Wells Fargo »

Parker-Hannifin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMT

Kennametal

$37.44

1.11 (3.06%)

20:41
06/20/18
06/20
20:41
06/20/18
20:41
Downgrade
Kennametal rating change at Wells Fargo »

Kennametal downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNT

Syntel

$34.07

0.65 (1.94%)

20:40
06/20/18
06/20
20:40
06/20/18
20:40
Downgrade
Syntel rating change at Wells Fargo »

Syntel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MGTA

Magenta Therapeutics

$0.00

(0.00%)

20:28
06/20/18
06/20
20:28
06/20/18
20:28
Syndicate
Magenta Therapeutics 6.667M share IPO priced at $15.00 »

The deal priced in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

XERS

Xeris Pharmaceuticals

$0.00

(0.00%)

20:26
06/20/18
06/20
20:26
06/20/18
20:26
Syndicate
Xeris Pharmaceuticals 5.7M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

KR

Kroger

$26.21

0.21 (0.81%)

, DRI

Darden

$93.27

-1.34 (-1.42%)

20:25
06/20/18
06/20
20:25
06/20/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$26.21

0.21 (0.81%)

DRI

Darden

$93.27

-1.34 (-1.42%)

CMC

Commercial Metals

$23.67

0.44 (1.89%)

PDCO

Patterson Companies

$22.54

0.07 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

  • 21

    Jun

  • 21

    Jun

  • 28

    Jun

  • 10

    Jul

IIIV

i3 Verticals

$0.00

(0.00%)

20:24
06/20/18
06/20
20:24
06/20/18
20:24
Syndicate
i3 Verticals 6.65M share IPO priced at $13.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

KZR

Kezar Life Sciences

$0.00

(0.00%)

20:23
06/20/18
06/20
20:23
06/20/18
20:23
Syndicate
Kezar Life Sciences 5M share IPO priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

LPL

LG Display

$8.91

-0.015 (-0.17%)

20:08
06/20/18
06/20
20:08
06/20/18
20:08
Periodicals
LG Display discussing early retirement options for workers, Bloomberg reports »

LG Display is considering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGO

Eldorado Gold

$1.13

-0.02 (-1.75%)

20:05
06/20/18
06/20
20:05
06/20/18
20:05
Hot Stocks
Eldorado Gold provides update on Lamaque exploration and development »

Eldorado Gold is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, RSX

Market Vectors Russia ETF

$20.52

0.22 (1.08%)

19:43
06/20/18
06/20
19:43
06/20/18
19:43
Periodicals
Trump planning to meet with Russia's Putin in Europe next month, Bloomberg says »

Donald Trump and…

SPX

S&P 500

$0.00

(0.00%)

RSX

Market Vectors Russia ETF

$20.52

0.22 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEO

CNOOC

$163.48

2.345 (1.46%)

19:29
06/20/18
06/20
19:29
06/20/18
19:29
Periodicals
CNOOC to proceed with expansion in Canada's oil sands, Reuters reports »

CNOOC's Nexen Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$134.34

-1.815 (-1.33%)

19:14
06/20/18
06/20
19:14
06/20/18
19:14
Periodicals
Toyota to reduce marketing costs to fund new research, Reuters reports »

Toyota Motors has started…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$202.08

4.62 (2.34%)

, GOOG

Alphabet

$1,169.38

1.52 (0.13%)

19:06
06/20/18
06/20
19:06
06/20/18
19:06
Periodicals
FTC chair wants to explore market power of big internet firms, Reuters says »

New U.S. Federal Trade…

FB

Facebook

$202.08

4.62 (2.34%)

GOOG

Alphabet

$1,169.38

1.52 (0.13%)

GOOGL

Alphabet Class A

$1,183.83

5.54 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

RYAAY

Ryanair

$117.11

3.54 (3.12%)

19:01
06/20/18
06/20
19:01
06/20/18
19:01
Periodicals
IAG, Ryanair preparing EU legal challenge over air traffic strikes, FT reports »

IAG and Ryanair are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNED

Barnes & Noble Education

$6.78

0.3 (4.63%)

, MU

Micron

$58.97

-0.26 (-0.44%)

19:00
06/20/18
06/20
19:00
06/20/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Barnes…

BNED

Barnes & Noble Education

$6.78

0.3 (4.63%)

MU

Micron

$58.97

-0.26 (-0.44%)

SCS

Steelcase

$15.55

0.2 (1.30%)

LITE

Lumentum

$56.45

0.8 (1.44%)

HPQ

HP Inc.

$23.31

-0.215 (-0.91%)

THO

Thor Industries

$104.81

6.5 (6.61%)

GLW

Corning

$28.40

0.015 (0.05%)

AOBC

American Outdoor Brands

$13.22

0.13 (0.99%)

LMNR

Limoneira

$26.65

0.63 (2.42%)

VERI

Veritone

$21.52

-0.64 (-2.89%)

TRUP

Trupanion

$41.07

0.8 (1.99%)

ARRS

Arris

$25.51

0.015 (0.06%)

WIX

Wix.com

$107.70

1.15 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 21

    Jun

  • 22

    Jun

  • 09

    Jul

  • 10

    Jul

  • 11

    Jul

  • 12

    Jul

  • 21

    Jun

  • 21

    Jun

  • 21

    Jun

DIS

Disney

$107.28

1.08 (1.02%)

18:55
06/20/18
06/20
18:55
06/20/18
18:55
Periodicals
Disney puts future 'Star Wars' spinoffs on hold, Collider reports »

Disney's Lucasfilm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$276.00

0.52 (0.19%)

, SPX

S&P 500

$0.00

(0.00%)

18:54
06/20/18
06/20
18:54
06/20/18
18:54
Periodicals
Trump sees U.S. quarterly GDP going much higher, Bloomberg reports »

Says the head of U.S.…

SPY

SPDR S&P 500 ETF Trust

$276.00

0.52 (0.19%)

SPX

S&P 500

$0.00

(0.00%)

X

U.S. Steel

$35.72

0.56 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,169.38

1.52 (0.13%)

, GOOGL

Alphabet Class A

$1,183.83

5.54 (0.47%)

18:51
06/20/18
06/20
18:51
06/20/18
18:51
Hot Stocks
Senators Cotton, Rubio urge Google to reconsider work with Huawei »

Senator Tom Cotton along…

GOOG

Alphabet

$1,169.38

1.52 (0.13%)

GOOGL

Alphabet Class A

$1,183.83

5.54 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.